Castle Biosciences (CSTL) Stock News
$CSTL · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Castle Biosciences (CSTL) in the past 30 days. CSTL last closed at $34.42 on Oct 9, down 3.21% over five sessions and up 6.50% over the past month. Castle Biosciences’ next earnings report is scheduled for Monday, Nov 2.
The wire on $CSTL
newest first · updated · direct subject stories onlyCastle Biosciences study shows TissueCypher changed management in 90% of NDBE patients
Castle Biosciences (CSTL) announced a study published in Foregut showing its TissueCypher test changed management recommendations in 90% of patients with non-dysplastic Barrett's Esophagus at Keck Medical Center of USC. The test classified 17% as intermediate or high risk and 83% as low risk. Management was escalated for all higher-risk patients and de-escalated for 84% of low-risk patients. The study was also presented at the American College of Surgeons Clinical Congress.
neutral 50 · impact 40